Journal of Cancer Metastasis and Treatment,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 30, 2024
Hypertension
is
a
known
risk
factor
for
clear
cell
renal
carcinoma
(ccRCC),
yet
the
underlying
mechanisms
remain
elusive.
Studies
have
confirmed
that
renin-angiotensin
system
(RAS)
plays
role
beyond
regulating
blood
pressure,
influencing
various
aspects
of
tumor
development
and
metastasis.
Generally,
activation
angiotensin-converting
enzyme
(ACE)/angiotensin
II
(Ang
II)/angiotensin
type
1
receptor
(AT1R)
axis
elevates
pressure
promotes
progression,
while
2
(ACE2)/[Ang-(1-7)]/Mas
(MasR)
antagonizes
these
effects.
Consequently,
many
cardiovascular
drugs
targeting
RAS
may
possess
both
hypotensive
antitumor
properties.
However,
in
ccRCC
controversial.
To
explore
this,
we
reviewed
relevant
literature.
Surprisingly,
apart
from
ACE2,
facilitate
progression
metastasis
ccRCC.
This
unexpected
finding
suggests
caution
when
using
inhibitors
patients.
review
provides
an
overview
RAS,
highlights
research
advances
ccRCC,
elucidates
current
status
RAS-targeted
treatment
discusses
challenges
future
directions
this
field.
In
conclusion,
upregulation
other
effector
peptides
receptors
expedite
progression.
Therefore,
careful
consideration
needed
patients
with
hypertension.
synthesis
available
evidence
crucial
informing
clinical
management
guiding
novel
therapeutic
strategies.
Naturally
occurring
extracellular
vesicles
(EVs)
and
synthetic
nanoparticles
like
liposomes
have
revolutionized
precision
diagnostics
medicine.
EVs
excel
in
biocompatibility
cell
targeting,
while
offer
enhanced
drug
loading
capacity
scalability.
The
clinical
translation
of
is
hindered
by
challenges
including
low
yield
heterogeneity,
whereas
face
rapid
immune
clearance
limited
targeting
efficiency.
To
bridge
these
gaps,
biomimetic
(SVs)
emerged
as
innovative
platforms,
combining
the
advantageous
properties
liposomes.
This
review
emphasizes
critical
aspects
EV
biology,
such
mechanisms
EV-cell
interaction
source-dependent
functionalities
modulation,
tissue
regeneration,
informing
SV
engineering.
We
reviewed
a
broad
array
SVs,
with
focus
on
lipid
bilayered
functionalized
proteins.
These
include
cell-derived
nanovesicles,
protein-functionalized
liposomes,
hybrid
vesicles.
By
addressing
current
highlighting
opportunities,
this
aims
to
advance
SVs
for
transformative
biomedical
applications.
ACS Nano,
Год журнала:
2024,
Номер
18(26), С. 16359 - 16394
Опубликована: Июнь 11, 2024
Glioblastoma
(GBM)
remains
the
epitome
of
aggressiveness
and
lethality
in
spectrum
brain
tumors,
primarily
due
to
blood–brain
barrier
(BBB)
that
hinders
effective
treatment
delivery,
tumor
heterogeneity,
presence
treatment-resistant
stem
cells
contribute
recurrence.
Nanoparticles
(NPs)
have
been
used
overcome
these
obstacles
by
attaching
targeting
ligands
enhance
therapeutic
efficacy.
Among
ligands,
peptides
stand
out
their
ease
synthesis
high
selectivity.
This
article
aims
review
single
multiligand
strategies
critically.
In
addition,
it
highlights
other
integrate
effects
external
stimuli,
biomimetic
approaches,
chemical
approaches
as
nanocatalytic
medicine,
revealing
significant
potential
treating
GBM
with
peptide-functionalized
NPs.
Alternative
routes
parenteral
administration,
specifically
nose-to-brain
delivery
local
within
resected
cavity,
are
also
discussed.
Finally,
an
overview
them
discussed
provide
a
perspective
on
this
promising
field
therapy.
Cancers,
Год журнала:
2024,
Номер
16(4), С. 823 - 823
Опубликована: Фев. 18, 2024
Gliomas,
the
most
prevalent
primary
malignant
brain
tumors,
present
a
challenging
prognosis
even
after
undergoing
surgery,
radiation,
and
chemotherapy.
Exosomes,
nano-sized
extracellular
vesicles
secreted
by
various
cells,
play
pivotal
role
in
glioma
progression
contribute
to
resistance
against
chemotherapy
radiotherapy
facilitating
transportation
of
biological
molecules
promoting
intercellular
communication
within
tumor
microenvironment.
Moreover,
exosomes
exhibit
remarkable
ability
traverse
blood–brain
barrier,
positioning
them
as
potent
carriers
for
therapeutic
delivery.
These
attributes
hold
promise
enhancing
diagnosis,
prognosis,
treatment.
Recent
years
have
witnessed
significant
advancements
exosome
research
realm
tumors.
In
this
article,
we
primarily
focus
on
elucidating
development,
highlighting
latest
breakthroughs
diagnostic
approaches,
outlining
prospective
directions
future
research.
Nanomaterials,
Год журнала:
2024,
Номер
14(7), С. 639 - 639
Опубликована: Апрель 6, 2024
Exosomes
are
spherical
extracellular
nanovesicles
with
an
endosomal
origin
and
unilamellar
lipid-bilayer
structure
sizes
ranging
from
30
to
100
nm.
They
contain
a
large
range
of
proteins,
lipids,
nucleic
acid
species,
depending
on
the
state
vesicle
(EV)-secreting
cell.
EVs’
function
is
encapsulate
part
EV-producing
cell
content,
transport
it
through
biological
fluids
targeted
recipient,
deliver
their
cargos
specifically
within
aimed
recipient
cells.
Therefore,
exosomes
considered
be
potential
drug-delivery
systems
that
can
stably
cargo
into
Various
cell-derived
produced
for
medical
issues,
but
use
therapeutic
purposes
still
faces
several
problems.
Some
these
difficulties
avoided
by
resorting
hemisynthetic
approaches.
We
highlight
here
uses
alternative
exosome-mimes
involving
cell-membrane
coatings
artificial
nanocarriers
or
hybridization
between
liposomes.
also
detail
drug-loading
strategies
deployed
make
them
drug-carrier
summarize
ongoing
clinical
trials
exosome-like
structures.
Finally,
we
open
questions
before
considering
disposals
confident
delivery.
Pharmacological Research,
Год журнала:
2024,
Номер
206, С. 107308 - 107308
Опубликована: Июль 15, 2024
Glioma
is
the
most
common
intracranial
malignant
tumor,
with
severe
difficulty
in
treatment
and
a
low
patient
survival
rate.
Due
to
heterogeneity
invasiveness
of
tumors,
lack
personalized
clinical
design,
physiological
barriers,
it
often
difficult
accurately
distinguish
gliomas,
which
dramatically
affects
subsequent
diagnosis,
imaging
treatment,
prognosis.
Fortunately,
nano-delivery
systems
have
demonstrated
unprecedented
capabilities
diagnosing
treating
gliomas
recent
years.
They
been
modified
surface
efficiently
traverse
BBB/BBTB,
target
lesion
sites,
intelligently
release
therapeutic
or
contrast
agents,
thereby
achieving
precise
treatment.
In
this
review,
we
focus
on
systems.
Firstly,
provide
an
overview
standard
emerging
diagnostic
technologies
for
glioma
practice.
After
induction
analysis,
summarizing
delivery
methods
drug
systems,
design
nanoparticles,
their
new
advances
Finally,
discussed
prospects
potential
challenges
drug-delivery
glioma.
European Journal of Pharmaceutics and Biopharmaceutics,
Год журнала:
2024,
Номер
203, С. 114460 - 114460
Опубликована: Авг. 31, 2024
Glioblastoma
(GBM)
stands
for
the
most
common
and
aggressive
type
of
brain
tumour
in
adults.
It
is
highly
invasive,
which
explains
its
short
rate
survival.
Little
known
about
risk
factors,
current
therapy
still
ineffective.
Hence,
efforts
are
underway
to
develop
novel
effective
treatment
approaches
against
this
cancer.
Exosomes
being
explored
as
a
promising
strategy
conveying
delivering
therapeutic
cargo
GBM
cells.
They
can
fuse
with
cell
membrane
and,
consequently,
serve
delivery
systems
context.
Due
their
nanoscale
size,
exosomes
cross
blood-brain
barrier
(BBB),
constitutes
significant
hurdle
chemotherapeutic
drugs
used
GBM.
subsequently
inhibit
oncogenes,
activate
suppressor
genes,
induce
immune
responses,
control
growth.
However,
despite
representing
tool
GBM,
further
research
clinical
studies
regarding
exosome
biology,
engineering,
applications
need
be
completed.
Here,
we
sought
review
application
through
an
in-depth
analysis
scientific
on
entire
process,
from
isolation
purification
design
transformation
into
anti-oncogenic
drug
systems.
Surface
modification
enhance
BBB
penetration
GBM-cell
targeting
also
topic
discussion.
